D. Baertschi

发表

Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).

D. Betticher, M. Schwenkglenks, D. Dietrich, 2016, Clinical colorectal cancer.

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

R. Herrmann, R. Winterhalder, M. Borner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.

A. Hinke, G. Tortora, V. Boige, 2021, Cancer treatment reviews.

O-0028BEVACIZUMAB CONTINUATION VERSUS NO CONTINUATION AFTER FIRST-LINE CHEMO-BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A PHASE 3 NON-INFERIORITY TRIAL

R. Herrmann, R. Winterhalder, M. Borner, 2013 .

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06).

R. Herrmann, R. Winterhalder, M. Borner, 2013 .

Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08).

R. Winterhalder, P. Wild, M. Borner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08).

R. Winterhalder, R. Cathomas, K. Zaugg, 2012 .

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

U. Hasler-Strub, C. Rochlitz, A. Mueller, 2022, Journal of geriatric oncology.

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.

R. Winterhalder, A. Wicki, D. Helbling, 2019, Journal of geriatric oncology.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

R. Winterhalder, G. Bodoky, F. Bosman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

R. Winterhalder, G. Bodoky, F. Bosman, 2015 .

1418PDLONG-TERM OUTCOME OF DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER TWO STAGE PHASE II TRIAL SAKK 56/07.

John O. Prior, B. Bui, P. Rutkowski, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

K. Zaman, R. Winterhalder, U. Hasler-Strub, 2014 .